

STATE OF SOUTH DAKOTA)
):SS:
COUNTY OF HUGHES)

IN CIRCUIT COURT
SIXTH JUDICIAL CIRCUIT

STATE OF SOUTH DAKOTA *ex rel.*
JASON R. RAVNSBORG, South
Dakota Attorney General,

32CIV18-000065

Plaintiff,

v.

PURDUE PHARMA L.P.; PURDUE
PHARMA, INC.; THE PURDUE
FREDERICK COMPANY, INC.;
JOHNSON & JOHNSON; JANSSEN
PHARMACEUTICALS, INC.; ORTHO-
MCNEIL-JANSSEN
PHARMACEUTICALS, INC. n/k/a
JANSSEN PHARMACEUTICALS, INC.;
JANSSEN PHARMACEUTICA INC.
n/k/a JANSSEN
PHARMACEUTICALS, INC.; ENDO
HEALTH SOLUTIONS INC.; ENDO
PHARMACEUTICALS, INC.; PAR
PHARMACEUTICAL, INC.; PAR
PHARMACEUTICAL COMPANIES,
INC. f/k/a PAR PHARMACEUTICAL
HOLDINGS, INC.; ALLERGAN PLC
f/k/a ACTAVIS PLC;
ALLERGAN FINANCE LLC, f/k/a
ACTAVIS INC., f/k/a WATSON
PHARMACEUTICALS, INC.; WATSON
LABORATORIES, INC., ACTAVIS LLC;
ACTAVIS PHARMA, INC. f/k/a
WATSON PHARMA, INC.;
MALLINCKRODT LLC; SPECGX LLC;
McKESSON CORPORATION;
CARDINAL HEALTH, INC.; CARDINAL
HEALTH 105, INC. d/b/a XIROMED,
LLC; CARDINAL HEALTH 108, LLC
f/k/a CARDINAL HEALTH 108, INC.;
CARDINAL HEALTH 110, LLC d/b/a
PARMED PHARMACEUTICALS;

**NOTICE OF ENTRY OF TEVA
CONSENT JUDGMENT AND
DISMISSAL WITH PREJUDICE**

CARDINAL HEALTH 200, LLC;
CARDINAL HEALTH 414, LLC;
CARDINAL HEALTH PHARMACY
SERVICES, LLC;
AMERISOURCEBERGEN DRUG
CORPORATION; WALGREENS
BOOTS ALLIANCE, INC.; WALGREEN
CO.; WALMART INC. f/k/a WAL-
MART STORES, INC; AND DOES 1
THROUGH 100, INCLUSIVE,


Defendants.

GREETINGS FROM THE STATE OF SOUTH DAKOTA TO THE ABOVE-NAMED
DEFENDANTS:

You will hereby take notice that on the 14th day of October 2023, the
above Court made and entered its Teva Consent Judgment and Dismissal with
Prejudice herein. Said Judgment was filed on October 16th 2023, with the
Hughes County Clerk of Courts. A true, correct and complete copy of the Teva
Consent Judgment and Dismissal with Prejudice, except, due to the exhibits
length, only the first page of the exhibits are attached, is hereunto annexed and
herewith served upon you and made a part of this notice the same as if fully
and completely set forth herein.

Dated this 7th day of November, 2023, at Pierre, South Dakota.

STATE OF SOUTH DAKOTA


Charles D. McGuigan
Deputy Attorney General
1302 East Highway 14, Suite 1
Pierre, SD 57501-8501
Telephone: (605) 773-3215
Email: Charles.McGuigan@state.sd.us

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on November _____, 2023, a true and correct copy of the Notice of Entry of Teva Consent Judgment was served electronically through Odyssey File & Serve or via email if the recipient(s) below are not registered with Odyssey system:

Sara Frankestein
Matthew E. Naasz
GUNDERSON, PALMER, NELSON, &
ASHMORE LLP
506Sixth Street
P.O. Box 8045
Rapid City, SD 57709-8045
(605) 342-7078
(605) 719-3471
sfrankenstein@gpna.com
mnaasz@gpna.com

Sheila L. Birnbaum (*admitted pro hac vice*)
Mark S. Cheffo (*admitted pro hac vice*)
Bert L. Wolff (*admitted pro hac vice*)
Jonathan S. Tam (*admitted pro hac vice*)
DECHERT LLP
Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
(212) 698-3500
Sheila.birnbaum@dechert.com
Mark.cheffo@dechert.com
Bert.wolff@dechert.com
Jonathan.tam@dechert.com

Attorney's for Purdue Pharma L.P., Purdue Pharma Inc., and The Purdue Frederick Company Inc.

Jeffery D. Collins
Thomas G. Fritz
Barbara Lewis
LYNN, JACKSON, SHULTZ & LEBRUN, PC
jcollins@lynnjackson.com
tfritz@lynnjackson.com
blewis@lynnjackson.com
Stephen D. Brody (*admitted pro hac vice*)
O'MELVENY & MYERS LLP

1625 Eye Street, NW
Washington, D.C. 20006
(202) 383-5300
sbrody@omm.com

Charles C. Lifland (*admitted pro hac vice*)
Justine M. Daniels (*admitted pro hac vice*)
O'MELVENY & MYERS LLP
400 S. Hope St.
Los Angeles, CA 90071
(213) 430-6000
clifland@omm.com
jdaniels@omm.com

Attorneys for Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc.

Eric C. Schulte
Anthony M. Hohn
DAVENPORT, EVANS, HURWITZ & SMITH LLP
eschulte@dehs.com
ahohn@dehs.com

Attorneys for Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.

Daniel R. Fritz
BALLARD SPAHR LLP
fritzd@ballardspahr.com

Attorney for Cardinal Health Inc.

Shawn M. Nichols
snichols@cadlaw.com

Attorney for Mallinckrodt, LLC and SpecGX, LLC

Robert Anderson
MAY, ADAM, GERDES & THOMPSON LLP
rba@mayadam.net

Attorney for Walgreens Boots Alliance Inc. and Walgreen Co.

Mark Haigh
Edwin E. Evans

EVANS HAIGH & ARNDT LLP
mhaigh@ehalawyers.com
eevans@ehalawyers.com

Attorneys for McKesson Corporation

Scott Abdallah
Erin Schoenbeck
Ronald A. Parsons, Jr.
scott@janklowabdallah.com
erin@janklowabdallah.com
ron@janklowabdallah.com

*Attorneys for Watson Laboratories, Inc. Actavis LLC & Actavis Pharma, Inc.
f/k/a Watson Pharma, Inc.*

Daniel F. Duffy
Emily Smoragiewicz
Karla Macarthur Harris
BANGS, MCCULLEN, BUTLER, FOYE & SIMMONS LLP
dduffy@bangsmccullen.com
emily@bangsmccullen.com
kmharris@bangsmccullen.com

Attorneys for AmerisourceBergen Drug Corporation

Gary D. Jensen
Jessica L. Larson
Matthew J. McIntosh
gjensen@blackhillslaw.com
jlarson@blackhillslaw.com
mmcintosh@blackhillslaw.com

Attorneys for Walmart Inc.

Jason R. Sutton
BOYCE LAW FIRM, L.L.P.
300 S. Main Avenue
jrsutton@boycelaw.com

KIRKLAND & ELLIS LLP
Jennifer G. Levy, P.C.
jennifer.levy@kirkland.com

KIRKLAND & ELLIS LLP
Donna Welch, P.C.
donna.welch@kirkland.com

*Attorneys for Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson
Pharmaceuticals, Inc. and Specially Appearing Allergan PLC f/k/a Actavis PLC*

Adam D. Teitcher
Morgan, Lewis & Bockius LLP
600 Anton Boulevard, Suite 1800
Costa Mesa, CA 92626
adam.teitcher@morganlewis.com

Brian M. Ercole
Morgan, Lewis & Bockius LLP
200 South Biscayne Boulevard, Suite 5300
Miami, FL 33131-2339
Brian.ercole@morganlewis.com


Steven A. Reed
Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, PA 19103-2921
Steven.reed@morganlewis.com

P. Benjamin Duke
Covington & Burling LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
pbduke@cov.com

Michael M. Maya
Covington & Burling LLP
One City Center
850 Tenth Street, NW
Washington, DC 20001-4956
mmaya@cov.com

Dated this 7th day of November 2023.

STATE OF SOUTH DAKOTA



Charles D. McGuigan
Deputy Attorney General
1302 East Highway 14, Suite 1
Pierre, SD 57501-8501
Telephone: (605) 773-3215
Email: Charles.McGuigan@state.sd.us

OF COUNSEL:

BARON & BUDD, P.C.

Russell Budd (*pro hac vice*)
Christine Mansour (*pro hac vice*)
3102 Oak Lawn Ave #1100
Dallas, TX 75219
(214) 521-3605
rbudd@baronbudd.com
cmansour@baronbudd.com

J. Burton LeBlanc, IV (*pro hac vice*)
2600 Citiplace Dr.
Baton Rouge, LA 70808
(225) 927-5441
bleblanc@baronbudd.com

Mark Pifko (*pro hac vice*)
15910 Ventura Blvd., Suite 1600
Encino, CA 91436
(818) 839-2333
mpifko@baronbudd.com

Jennifer Fountain Connolly (*pro hac vice*)
600 New Hampshire Avenue NW
10th Floor
Washington, DC 20037
(202) 333-4562
jconnolly@baronbudd.com

STATE OF SOUTH DAKOTA)
)
) :SS:
)
COUNTY OF HUGHES)

IN CIRCUIT COURT
SIXTH JUDICIAL CIRCUIT

STATE OF SOUTH DAKOTA *ex rel.*
JASON R. RAVNSBORG, South
Dakota Attorney General,

32CIV18-000065

Plaintiff,

v.

PURDUE PHARMA L.P.; PURDUE
PHARMA, INC.; THE PURDUE
FREDERICK COMPANY, INC.;
JOHNSON & JOHNSON; JANSSEN
PHARMACEUTICALS, INC.; ORTHO-
MCNEIL-JANSSEN
PHARMACEUTICALS, INC. n/k/a
JANSSEN PHARMACEUTICALS, INC.;
JANSSEN PHARMACEUTICA INC.
n/k/a JANSSEN
PHARMACEUTICALS, INC.; ENDO
HEALTH SOLUTIONS INC.; ENDO
PHARMACEUTICALS, INC.; PAR
PHARMACEUTICAL, INC.; PAR
PHARMACEUTICAL COMPANIES,
INC. f/k/a PAR PHARMACEUTICAL
HOLDINGS, INC.; ALLERGAN PLC
f/k/a ACTAVIS PLC;
ALLERGAN FINANCE LLC, f/k/a
ACTAVIS INC., f/k/a WATSON
PHARMACEUTICALS, INC.; WATSON
LABORATORIES, INC., ACTAVIS LLC;
ACTAVIS PHARMA, INC. f/k/a
WATSON PHARMA, INC.;
MALLINCKRODT LLC; SPECGX LLC;
McKESSON CORPORATION;
CARDINAL HEALTH, INC.; CARDINAL
HEALTH 105, INC. d/b/a XIROMED,
LLC; CARDINAL HEALTH 108, LLC
f/k/a CARDINAL HEALTH 108, INC.;
CARDINAL HEALTH 110, LLC d/b/a
PARMED PHARMACEUTICALS;

**TEVA
CONSENT JUDGMENT AND
DISMISSAL WITH PREJUDICE**

CARDINAL HEALTH 200, LLC;
CARDINAL HEALTH 414, LLC;
CARDINAL HEALTH PHARMACY
SERVICES, LLC;
AMERISOURCEBERGEN DRUG
CORPORATION; WALGREENS
BOOTS ALLIANCE, INC.; WALGREEN
CO.; WALMART INC. f/k/a WAL-
MART STORES, INC; AND DOES 1
THROUGH 100, INCLUSIVE,

Defendants.

FINAL CONSENT JUDGMENT AND DISMISSAL WITH PREJUDICE

The State of South Dakota (“*State*”) and Actavis LLC, Watson Laboratories, Inc., and Actavis Pharma, Inc. f/k/a Watson Pharma, Inc. (collectively, “*Teva*”¹ or “*Defendants*”) (together with the State, the “*Parties*,” and each a “*Party*”) have entered into a consensual resolution of the above-captioned litigation (the “*Action*”) pursuant to a settlement agreement entitled Teva Global Opioid Settlement Agreement, dated as of November 22, 2022 (as subsequently updated) (the “*Agreement*”), a copy of which is attached hereto as Exhibit A. The Agreement shall become effective by its terms upon the entry of this Final Consent Judgment (the “*Judgment*”) by the Court without trial or adjudication of any contested issue of fact or law, and without finding or admission of wrongdoing or liability of any kind.

¹ This Consent Judgment resolves litigation as to “*Teva*” as the term is defined in the Teva Global Opioid Settlement Agreement, which definition includes (i) Teva Pharmaceutical Industries Ltd. and (ii) all of its respective past and present direct or indirect parents, subsidiaries, divisions, affiliates, joint ventures, predecessors, successors, assigns, including but not limited to Teva Pharmaceuticals USA, Inc., the Actavis Generic Entities, and Anda Inc.

RECITALS:

1. Each Party warrants and represents that it engaged in arm's-length negotiations in good faith. In hereby executing the Agreement, the Parties intend to effect a good-faith settlement.

2. The State has determined that the Agreement is in the public interest.

3. Teva denies the allegations against it and that it has any liability whatsoever to the State, its Subdivisions, its Special Districts, and/or (a) any of the State's or Subdivisions' or Special Districts' departments, agencies, divisions, boards, commissions, districts, instrumentalities of any kind and attorneys, including its Attorney General and any person in his or her official capacity whether elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, and other Special Districts in the State, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief on behalf of or generally applicable to the general public.

4. The Parties recognize that the outcome of the Action is uncertain and a final resolution through the adversarial process likely will require protracted litigation.

5. The Parties agree to the entry of the injunctive relief terms pursuant to Exhibits P and Q of the Agreement.

6. Therefore, without any admission of liability or wrongdoing by Teva or any other Released Entities (as defined in the Agreement), the Parties now mutually consent to the entry of this Judgment and agree to dismissal of the claims with prejudice pursuant to the terms of the Agreement to avoid the delay, expense, inconvenience, and uncertainty of protracted litigation.

NOW THEREFORE, IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:

In consideration of the mutual promises, terms, and conditions set forth in the Agreement, the adequacy of which is hereby acknowledged by all Parties, it is agreed by and between Defendants and the State, and adjudicated by the Court, as follows:

1. The foregoing Recitals are incorporated herein and constitute an express term of this Judgment.

2. The Parties have entered into a full and final settlement of all Released Claims of Releasers (as defined in the Agreement) against Teva (including but not limited to the State) and the Released Entities pursuant to the terms and conditions set forth in the Agreement.

3. The "Definitions" set forth in Section I of the Agreement are incorporated by reference into this Judgment. The State is a "Settling State" within the meaning of the Agreement. Unless otherwise defined herein, capitalized terms in this Judgment shall have the same meaning given to them in the Agreement.

4. The Parties agree that the Court has jurisdiction over the subject matter of the Action and over the Parties with respect to the Action and this Judgment. This Judgment shall not be construed or used as a waiver of any jurisdictional defense Teva or any other Released Entity may raise in any other proceeding.

5. The Court finds that the Agreement was entered into in good faith.

6. The Court finds that entry of this Judgment is in the public interest and reflects a negotiated settlement agreed to by the Parties. The Action is dismissed with prejudice, subject to a retention of jurisdiction by the Court as provided herein and in the Agreement.

7. By this Judgment, the Agreement is hereby approved by the Court, and the Court hereby adopts the Agreement's terms as its own determination of this matter and the Parties' respective rights and obligations.

8. The Court shall have authority to resolve disputes identified in Section XV.G.2 of the Agreement, governed by the rules and procedures of the Court.

9. By this Judgment, Teva Global Opioid Settlement Agreement *and the South Dakota Opioid Settlement Memorandum of Agreement*, a copy of which is attached hereto as Exhibit C and as incorporated into the Agreement pursuant to Exhibit O of the Agreement, is hereby approved by the Court as the means by which relevant funds paid pursuant to the Agreement will be divided within the State, subject to the full acceptance by any Subdivision or Special District receiving such funds of the terms of the Agreement, including the releases provided therein. Also see SDCL 34-20B-1.

10. The Parties have satisfied the Condition to Effectiveness of Agreement set forth in Section XI of the Agreement and the Release set forth in Sections V.A, D, and E of the Agreement, as follows:

- a. The Attorney General of the State exercised the fullest extent of his or her powers to release Teva and all other Released Entities from all Released Claims pursuant to the release attached hereto as Exhibit B (the "Release").
- b. Teva has determined that there is sufficient State participation and sufficient resolution of the Claims of the Litigating Subdivisions and Litigating Special Districts in the Settling States to proceed with the Agreement.
- c. The Settlement Participation Form for each Initial Participating Subdivision and Initial Participating Special District in the State has been delivered to Teva. As stated in the Settlement Participation Form, and for the avoidance of doubt, nothing in the Settlement Participation Form executed by the Participating Subdivisions and Participating Special Districts is intended to modify in any way the terms of the Agreement to which the Participating Subdivisions and Participating Special Districts agree. As stated in the Settlement Participation Form, to the extent the executed version of the Settlement Participation Form differs from the Agreement in any respect, the Agreement controls.
- d. Pursuant to the Settlement Participation Form, each Participating Subdivision and Participating Special District in the State is dismissing with prejudice any Released Claims that it has filed against Teva and the Released Entities.

11. Release. The Parties acknowledge that the Release, which is incorporated by reference herein, is an integral part of this Judgment. Pursuant to the Agreement and the Release and without limitation and to the maximum extent of the power of the State's Attorney General, Teva and the other Released Entities are, as of the Effective Date, hereby released from any and all Released Claims of (a) the State, its Participating Subdivisions, its Participating Special Districts and any of their departments, agencies, divisions, boards, commissions, Subdivisions, districts, instrumentalities of any kind and attorneys, including the State's Attorney General, and any person in his or her official capacity whether elected or appointed to serve any of the foregoing, and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, water districts, emergency services districts, school districts, healthcare districts, hospital districts, and Sheriffs and law enforcement districts, library districts, coroner's offices, and public transportation authorities, and other Special Districts in the State, including those with the regulatory authority to enforce state and federal controlled substances acts or the authority to bring Claims related to Covered Conduct seeking money (including abatement (or remediation and/or restitution)) or revoke a pharmaceutical distribution license, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief, including but not limited to, fines, penalties, or punitive damages, on behalf of or generally applicable to the general public with respect to the State or any Subdivision or Special District in the State, whether or not any of them participate in the Agreement. Pursuant to the Agreement and the Release and to the maximum extent of the State's power, Teva and the other Released Entities are, as of the Effective Date, hereby released from any and all Released Claims of (1) the State, (2) all past and present executive departments,

state agencies, divisions, boards, commissions and instrumentalities with the regulatory authority to enforce state and federal controlled substances acts, (3) any of the State's past and present executive departments, agencies, divisions, boards, commissions and instrumentalities that have the authority to bring Claims related to Covered Conduct seeking money (including abatement and/or remediation) or revocation of a pharmaceutical distribution license, (4) any Participating Subdivision, and (5) any Participating Special District. For the purposes of clause (3) above, executive departments, agencies, divisions, boards, commissions, and instrumentalities are those that are under the executive authority or direct control of the State's Governor. Further, the provisions set forth in Section V of the Agreement are incorporated by reference into this Judgment as if fully set forth herein. The Parties acknowledge, and the Court finds, that those provisions are an integral part of the Agreement and this Judgment, and shall govern the rights and obligations of all participants in the settlement. Any modification of those rights and obligations may be made based only on a writing signed by all affected parties and approved by the Court.

12. Release of Unknown Claims. The State expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to § 1542 of the California Civil Code, which reads:

General Release; extent. A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

13. The State may hereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims, but the State expressly waived and fully, finally, and forever settled, released and discharged, through the Agreement and Release, any and all Released Claims that may exist as of the Effective Date but which the State does not

know or suspect to exist, whether through ignorance, oversight, error, negligence or through no fault whatsoever, and which, if known, would have materially affected the State's decision to enter into the Agreement.

14. Costs and Fees. The Parties will bear their own costs and attorneys' fees except as otherwise provided in the Agreement.

15. No Admission of Liability. Defendants are consenting to this Judgment solely for the purpose of effectuating the Agreement, and nothing contained herein may be taken as or construed to be an admission or concession of any violation of law, rule, or regulation, or of any other matter of fact or law, or of any liability or wrongdoing, all of which Defendants expressly deny. No Defendant or Released Entity admits that it caused or contributed to any public nuisance, and no Defendant or Released Entity admits any wrongdoing that was or could have been alleged by the State, its Participating Subdivisions and/or Participating Special Districts, or any other person or entity. No part of this Judgment shall constitute evidence of any liability, fault, or wrongdoing by Defendants or any other Released Entity. The Parties acknowledge that payments made under the Agreement are not a fine, penalty, or payment in lieu thereof and are properly characterized as described in Section VIII.G of the Agreement.

16. No Waiver. This Judgment is entered based on the Agreement without trial or adjudication of any contested issue of fact or law or finding of liability of any kind. This Judgment shall not be construed or used as a waiver of Teva's right, or any other Released Entity's right, to defend itself from, or make any arguments in, any other regulatory, governmental, private individual, or class claims or suits relating to the subject matter or terms of this Judgment.

Notwithstanding the foregoing, the State may enforce the terms of this Judgment as expressly provided in the Agreement.

17. No Private Right of Action. This Judgment is not intended for use by any third party for any purpose, including submission to any court for any purpose, except pursuant to Section XV.A of the Agreement. Except as expressly provided in the Agreement, no portion of the Agreement or this Judgment shall provide any rights to, or be enforceable by, any person or entity that is not a Settling State or Released Entity. The State shall allow Participating Subdivisions and Participating Special Districts in the State to notify it of any perceived violations of the Agreement or this Judgment. No Settling State, including the State, may assign or otherwise convey any right to enforce any provision of the Agreement.

18. Admissibility. It is the intent of the Parties that this Judgment not be admissible in other cases against Defendants or binding on Defendants in any respect other than in connection with the enforcement of this Judgment or the Agreement. For the avoidance of doubt, nothing herein shall prohibit Defendants from entering this Judgment or the Agreement into evidence in any litigation or arbitration concerning (1) Defendants' right to coverage under an insurance contract or (2) the enforcement of the releases provided for by the Agreement and this Judgment.

19. Preservation of Privilege. Nothing contained in the Agreement or this Judgment, and no act required to be performed pursuant to the Agreement or this Judgment, is intended to constitute, cause, or effect any waiver (in whole or in part) of any attorney-client privilege, work product protection, or common interest/joint defense privilege, and each Party agrees that it shall not make or cause to be made in any forum any assertion to the contrary.

20. Mutual Interpretation. The Parties agree and stipulate that the Agreement was negotiated on an arm's-length basis between parties of equal bargaining power and was drafted

jointly by counsel for each Party. Accordingly, the Agreement is incorporated herein by reference and shall be mutually interpreted and not construed in favor of or against any Party, except as expressly provided for in the Agreement.

21. Retention of Jurisdiction. The Court shall retain jurisdiction of the Parties for the limited purpose of the resolution of disputes identified in Section XV.G.2 of the Agreement. The Court shall have jurisdiction over Participating Subdivisions and Participating Special Districts in the State for the limited purposes identified in the Agreement.

22. Successors and Assigns. This Judgment is binding on Defendants' successors and assigns.

23. Modification. This Judgment shall not be modified (by the Court, by any other court, or by any other means) without the consent of the State and Defendants, or as provided for in Section XVI.T of the Agreement.

So ORDERED this 14th day of October 2023.

BY THE COURT:



The Honorable David R. Gienapp,
Circuit Court Judge, Retired

Attest:
Deuter-Cross, TaraJo
Clerk/Deputy



APPROVED, AGREED TO AND PRESENTED BY:

FOR THE STATE OF SOUTH DAKOTA

/s/ Charles D. McGuigan

Charles D. McGuigan
Deputy Attorney General
1302 East Highway 14, Suite 1
Pierre, SD 57501-8501
Telephone: (605) 773-3215
Email: Charles.McGuigan@state.sd.us

FOR TEVA

RAPARSONS 10/4/2023

Ronald A. Parsons, Jr.
Attorney at Law
Johnson, Janklow, & Abdallah, L.L.P.
101 South Main Avenue, Suite 100
Sioux Falls, SD 57104
Email: ron@janklowabdallah.com

TEVA GLOBAL OPIOID SETTLEMENT AGREEMENT

I.	Definitions	2
II.	Participation by States and Condition to Preliminary Agreement	18
III.	Cessation of Litigation Activities	18
IV.	Injunctive Relief	19
V.	Release	19
VI.	Monetary Relief Overview and Maximum Payments	24
VII.	Annual Payments to Settlement Fund	25
VIII.	Allocation and Use of Settlement Funds	36
IX.	Settlement Product	43
X.	Participation by Subdivisions and Special Districts	45
XI.	Condition to Effectiveness of Agreement and Filing of Consent Judgment	49
XII.	Potential Payment Adjustments	50
XIII.	Additional Restitution Amount	51
XIV.	Plaintiffs' Attorneys' Fees and Costs	51
XV.	Enforcement and Dispute Resolution	51
XVI.	Miscellaneous	58

**Attorney General's Release of Opioid-Related Claims Pursuant to the
Teva Global Opioid Settlement Agreement**

WHEREAS the Teva Global Opioid Settlement Agreement dated November 22, 2022 (the "Agreement") provides in Section V.A that, as of the Effective Date of the Agreement, Teva and the Released Entities will be released and forever discharged from all of the Releasors' Released Claims;¹ and

WHEREAS the Agreement provides in Section I.77 that Releasors (as defined in the Agreement) who are releasing claims under Section V.A include without limitation and to the maximum extent of the power of each Settling State's Attorney General to release Claims (a) the Settling State's, Participating Subdivision's and Participating Special District's departments, agencies, divisions, boards, commissions, Subdivisions, districts, instrumentalities of any kind and attorneys, including its Attorney General, and any person in his or her official capacity whether elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, water districts, emergency services districts, school districts, healthcare districts, hospital districts, Sheriffs and law enforcement districts, library districts, coroner's offices, and public transportation authorities, and other Special Districts in a Settling State, including those with regulatory authority to enforce state and federal controlled substances acts or the authority to bring Claims related to Covered Conduct seeking money (including abatement (or remediation and/or restitution)) or revoke a pharmaceutical distribution license, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief, including but not limited to, fines, penalties, or punitive damages, on behalf of or generally applicable to the general public with respect to a Settling State or a Subdivision or Special District in a Settling State, whether or not any of them participate in the Agreement; and

WHEREAS the Agreement provides in Section V.E that each Settling State's Attorney General expressly represents and warrants that he or she has, or has obtained, the authority to settle and release, to the maximum extent of the State's power, all Released Claims of (1) his or her respective Settling State, (2) all past and present executive departments, state agencies, divisions, boards, commissions and instrumentalities with the regulatory authority to enforce state and federal controlled substances acts, and (3) any of his or her respective Settling State's past and present executive departments, agencies, divisions, boards, commissions and instrumentalities that have the authority to bring Claims related to Covered Conduct seeking money (including abatement and/or remediation) or revocation of a pharmaceutical distribution license. For the purposes of clause (3) above, executive departments, agencies, divisions, boards, commissions, and instrumentalities are those that are under the executive authority or direct control of the State's Governor; *[and*

¹ Capitalized terms used herein and defined in the Agreement have the meanings given to them in the Agreement.

South Dakota Opioid Settlement

Memorandum of Agreement

Whereas, the people of the State of South Dakota and its communities have been harmed by serious and substantial wrongdoing committed by certain entities within the Pharmaceutical Supply Chain;

Whereas, the State of South Dakota, through its Attorney General, and certain Participating Local Governments have separately engaged in investigation, litigation, and settlement discussions seeking to hold Pharmaceutical Supply Chain Participants accountable for the damage they have caused in South Dakota;

Whereas, other Participating Local Governments, while not engaged in separate litigation, have supported the State's efforts in the legal fight against the opioid crisis;

Whereas, the State and all Participating Local Governments share a common desire to abate and alleviate the impacts of the Pharmaceutical Supply Chain Participants' misconduct throughout the State of South Dakota;

Whereas, jointly approaching Settlements with Pharmaceutical Supply Chain Participants benefits all Parties by improving the likelihood of successful Settlement and maximizing the recovery from any such Settlement;

Whereas, specifically, the State and Participating Local Governments understand that Settlements with major Pharmaceutical Supply Chain Participants have taken the form of a national resolution (National Settlement Agreement);

Whereas, the State and Participating Local Governments intend this agreement to facilitate their compliance with the terms of the National Settlement Agreement;

Whereas, the State and Participating Local Governments understand that the National Settlement Agreement provides a default allocation between each state and its political subdivisions unless they enter into a state-specific agreement regarding the distribution and use of payments (State-Subdivision Agreement);

Whereas, specifically, the State and Participating Local Governments intend this agreement to serve as a State-Subdivision Agreement under the National Settlement Agreement involving Johnson & Johnson, AmerisourceBergen, Cardinal Health, and McKesson, and Bankruptcy Resolutions concerning Purdue Pharma, L.P. and Mallinckrodt plc entered into by the State and the Participating Local Governments;

Now, therefore, in consideration of the foregoing, the State and its Participating Local Governments, enter into this "South Dakota Opioid Settlement Memorandum of Agreement" (MOA) relating to the allocation and use of the proceeds of any Settlement as described in this MOA;